Dr. Charalampos (Haris) Tzoulis, a Parkinson’s expert, and Professor of Neurology and Neurodegeneration at the University of Bergen is currently overseeing clinical trials studying NAD+ boosting vitamin supplement Nicotinamide Riboside “NR” (FAQs) (Anecdotes) as a possible treatment for Parkinson’s patients. In a recent presentation, Dr. Tzoulis explained why he chose to use NR as opposed to any other NAD+ precursor:

At the 20:45 mark of the presentation linked to below:

“There’s a number of different NAD precursors.

We chose to go with Nicotinamide Riboside or NR for many reasons.

One of the reasons was that NR was certainly the most well studied of the NAD precursors — and this is very important when we’re going to do human studies.

And it had repeatedly been proven to be safe both in a preclinical and a clinical setting.

The other advantage is that compared to Nicotinic acid or Niacin, NR doesn’t give any side effects.

Niacin is also safe — but is associated with very bothersome hot flashing and redness of the skin.

So, there are many reasons to go with NR.

And we chose as NR as our supplement of choice in this case”

RELATED:

  • You can watch the full presentation HERE
  • Parkinson’s Expert Explains Why He’s Aggressively Testing Nicotinamide Riboside in Parkinson’s Patients (Link)
  • NAD and Parkinson’s Disease – The Clinical Studies (Science of NAD)
  • FAQs on the Potential for Nicotinamide Riboside (NR) in Alzheimer’s Patients (Link)
  • Nicotinamide Riboside “NR” (FAQs) (Reviews)

FOLLOW us on Twitter @RaisingNAD